Podcasts about remap cap

What do you do when most trials suggest benefit for an intervention, but then a new trial suggests harm? We thought steroids in pneumonia was a settled question, but REMAP-CAP had other plans!We also review a new RCT for BP targets in patients with hypertension and diabetes, a new aldosterone synthase inhibitor for hypertension, and reduced dose apixaban for cancer-associated thrombosis. Hydrocortisone for Severe CAP (REMAP-CAP)Predicting Benefit of Corticosteroids in PneumoniaIntensive BP Control in Patients with Diabetes (BPROAD)Lorundrostat for Uncontrolled Hypertension (ADVANCE-HTN)Reduced Dose Apixaban for Cancer Associated Thrombosis (API-CAT)Music from Uppbeat (free for Creators!): https://uppbeat.io/t/soundroll/dope License code: NP8HLP5WKGKXFW2R

Dr Lisa Higgins (Melbourne) presents the long term outcomes of the REMAP-CAP domains at the Critical Care Reviews Meeting 2023. Prof Howard Bauchner (Boston) delivers an editorial. Prof Christopher Seymour (Pittsburgh) chairs the session.

Dr Francois Lamontagne joins Rob Mac Sweeney to discuss the harmonised REMAP-CAP / LOVIT-COVID vitamin C trial. The trial was presented at the European Society of Intensive Care Medicine annual congress and simultaneously published in the New England Journal of Medicine.

Scott Berry (Austin) and Danny McAuley (Belfast) join Rob Mac Sweeney to discuss the results of the statin domain of the REMAP-CAP trial, investigating 80mg once daily of simvastatin in critically ill patients with COVID-19.

This piece focuses upon the “REMAP-CAP” trial; A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia. It's a wide ranging discussion which looks behind the headlines of this fascinating piece of research. Their website is here: https://www.remapcap.org/ In the podcast you will hear Monty Mythen speaking with Steve Webb, Professor of Critical Care Research at Monash University, Director of Research for St John of God Healthcare, and a ICU consultant at St John of God Subiaco and the Mount Hospital and Doug Campbell, Anaesthetic specialist at Auckland City Hospital.

In this “Breathe Easy Critical Perspective” podcast, Dr. Dominique Pepper interviews Dr. Alisa Higgins. They discuss long-term outcomes in critically ill patients with COVID-19. Dr. Higgins is Senior Research Fellow at Monash University in Melbourne, Australia.

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the January 3, 2023, issue. Related Content: Audio Highlights

The last few years have been dominated by the global fight against COVID-19 and research efforts continue in search of new treatments and vaccines to save lives.Melbourne-based Dimerix Bioscience is a clinical-stage biopharmaceutical company investigating a new treatment for respiratory complications as a result of COVID 19 – which was selected for inclusion in the global WHO-endorsed clinical study REMAP-CAP investigating community-acquired pneumonia.Through MTPConnect's Biomedical Translation Bridge (BTB) Program, Dimerix was awarded $1 million in MRFF-funding for this COVID-19 related project. MTPConnect host Caroline Duell catches up with Dr Robert Shepherd, Research & Development Director at Dimerix Bioscience to find out more about this potential new treatment, the benefits and challenges of being part of a unique adaptive clinical trial program and how they managed to manufacture doses for the trial during the pandemic. https://dimerix.com/Uniquest is a Venture Partner in the BTB Program, and Cecile Francis, Uniquest's BTB Program Project Manager joins the discussion.  https://uniquest.com.au/

La fin d'année étant un moment propice pour les rétrospectives, Trait pharmacien a invité des membres de 7 regroupements de pharmaciens experts de l'A.P.E.S. à nous présenter un article marquant dans leur champ de pratique publié dans la dernière année. Que doit-on retenir de 2021 dans les domaines de l'infectiologie, des soins intensifs, de la cardiologie, de la néphrologie, de la psychiatrie, de la gériatrie et de l'urgence ? C'est ce dont nous discutons dans cet épisode ! RÉFÉRENCES : Infectiologie Drekonja, D, Trautner, B, Amundson, C et al. Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: A randomized clinical trial. JAMA. 2021;326(4):324-331. DOI:10.1001/jama.2021.9899 Soins intensifs The REMAP-CAP investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med 2021; 384:1491-1502. DOI: 10.1056/NEJMoa2100433 Cardiologie Anker, Stefan D et al. “Empagliflozin in heart failure with a preserved ejection fraction.” N Engl J Med 2021; 385:1451-1461. DOI: 10.1056/NEJMoa2107038 Néphro Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD trial committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436-1446. DOI: 10.1056/NEJMoa2024816 Psychiatrie Leucht S, Bauer S, Siafis, S et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: A meta-analysis. JAMA Psychiatry. 2021;78(11):1238-1248. DOI:10.1001/jamapsychiatry.2021.2130 Gériatrie Yourman L C, Cenzer I S, Boscardin J, Nguyen B et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 Years: A meta-analysis. JAMA Intern Med. 2021 Feb 1;181(2):179-185. DOI: 10.1001/jamainternmed.2020.6084. Urgence Moussavi K, Garcia J, Tellez-Corrales E, Fitter S. Reduced alternative insulin dosing in hyperkalemia: A meta-analysis of effects on hypoglycemia and potassium reduction. Pharmacotherapy. 2021; 41: 598– 607. https://doi.org/10.1002/phar.2596

Critical Care Reviews' Rob Mac Sweeney talks with Prof. Alistair Nichol about ivermectin, one of the latest interventions added to the REMAP-CAP trial. He explains why this intervention is implemented into the trial despite the controversy surrounding the use of ivermectin to treat COVID-19. 

Prof Alistair Nichol (Dublin & Melbourne) discusses why the REMAP-CAP adaptive platform trial has chosen to investigate ivermectin, given the controversy surrounding this agent.

Critical Care Reviews' Rob Mac Sweeney talks with  Dr. Lennie Derde about her background in critical care, infectious diseases and research, all the output generated by REMAP-CAP so far and her view on how this pandemic is likely to progress.

Dr Lennie Derde is the Trial Steering Committee Chair and the European Coordinating Investigator for the REMAP-CAP project. She discusses the running of the REMAP-CAP trial, her background in critical care and infectious diseases, how she got into critical care research, the background of the REMAP-CAP trial and its current workload for her. We also review the output from the trial to date and finish by considering how this pandemic is likely to progress.

Critical Care Reviews' Rob Mac Sweeney talks with professor Alistair Nichol about the new Ventilation domain of REMAP-CAP.

In the latest episode on the REMAP-CAP series, Prof Alistair Nichol (Dublin / Melbourne) discuss the upcoming ventilation domain with Rob Mac Sweeney.

Patients with COVID-19 have an increased risk of venous thromboembolism (VTE), but the best strategy for the prevention and care of VTE remains elusive. Observational studies have suggested that empiric full anticoagulation in patients with COVID-19 is ineffective or indeed harmful. Recently, however, multiple large platform trials (ACTIV-4a, ATTACC, and REMAP-CAP) have provided surprising new evidence in favor of full anticoagulation in selected populations. In this episode, our panel of experts review the newest data and provide insights on how we can best care for patients in this next phase of the pandemic. (Originally recorded April 1, 2021) Moderator: Jean M. Elwing, MD, FCCP. Panelists: Sandeep Sahay, MD; Dana Kay, DO; Parth Rali, MD; and Vijay Balasubramanian, MD. For more tools to help in the fight against COVID-19, visit CHEST's COVID-19 Resource Center at chestnet.org/COVID19.

In this episode, we discuss recently published practice-changing trials RECOVERY and REMAP-CAP. These trials have clearly demonstrated the difference in mortality with the use of Tocilizumab in severe COVID-19.  

Os corticosteróides são medicamentos amplamente utilizados na prática clínica diária.Com a pandemia da COVID-19, diversos estudos clínicos foram propostos e realizados com pacientes infectados a fim de testar os corticóides como intervenção.Em julho de 2020, foi publicado o primeiro grande trabalho controlado e randomizado sobre o tema: o ensaio clínico RECOVERY. Depois disso, mais três artigos originais foram publicados (CODEX, CAPE COVID e REMAP-CAP) simultaneamente com uma metanálise sobre o tema.Mas afinal, o que sabemos até o momento sobre corticosteróides no paciente crítico com COVID-19?Para discutir esse assunto fundamental e super atual, o “Corrida de Leito” dessa semana teve o prazer de contar com a participação do médico intensivista Dr. Rogério Sad, coordenador dos CTI adulto do hospital Governador Israel Pinheiro, o Ipsemg e do hospital Vera Cruz, ambos de Belo Horizonte e a médica intensivista Dra. Marcela Rangel, também coordenadora do CTI Adulto do hospital Ipsemg e médica plantonista do hospital Felício Rocho de Belo Horizonte.Fique ligado e não perca este bate papo!#coronavirus #covid19 #corticoides #corticoidenacovid #saragrave #dexametasona

“Ons land is totaal niet voorbereid op een pandemie, echt dramatisch” In de tweede aflevering van SignaalWaarde spreken Marino, Yorick, en Maarten met arts-microbioloog en epidemioloog prof.dr. Marc Bonten over de Nederlandse strategie, de opkomst van nieuwe varianten, alles rondom vaccins en vaccineren, en ze beantwoorden vragen van de luisteraars. Je kunt nu ook Vriend van de Show worden! Het is ook mogelijk op een andere manier bij te dragen aan de podcast. Tijdschema 00:03:10 - Een snelle start - “Dit gaat helemaal fout” 00:08:07- Strategie & zero covid 00:19:14 - Een blik op de toekomst 00:27:12 - Testen en infectiepreventie 00:34:00 - Vaccinatie - “elke spuit moet meteen in een arm” 00:47:29 - Sociale epidemiologie - “Er is elke week een ander dilemma” 00:52:21 - De komende 6 maanden 00:54:49 - De persoonlijke noot - “de schoonheid van de REMAP-CAP” 01:01:31 - Afkondiging Links Het paper van 23 januari over het reproductiegetal van het nieuwe coronavirus. En een beschouwing en het blog: “it giet oan”. De situatie in IJsland en Nieuw Zeeland. Het OMT advies over de R van 0,9 van 28 september: “Het OMT ziet een R(t) van 0,9 als bovengrens. (...) het [is] verstandig naar een lagere R(t) te streven en eerder een steviger pakket aan maatregelen te adviseren.” Thijs Kuiken die schrijft over aviaire influenza (vogelgriep). Over internationale samenwerkingen om betere behandelingen te vinden: REMAP-CAP study (A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia). RECOVER en PERPARE. PRINCIPLE study in primary care. WHO solidarity trial. Mooi overzicht van alle verschillende varianten bij Nextstrain. De CureVac trial in Nederland. Samenwerken in One Health. Contact Je kan ons altijd vragen stellen en suggesties doen via onze website signaalwaarde.nl maar we zijn natuurlijk ook te bereiken via Twitter: @signaalwaarde. Daarnaast kun je ons altijd mailen op signaalwaarde@gmail.com

Critical Care Reviews' Rob Mac Sweeney talks with professor Mathias Pletz about pandemics and the COVID-19 pandemic mode of REMAP-CAP.

Critical Care Reviews' Rob Mac Sweeney talks with professor John Marshall and assistant professor Srinivas Murthy about the interventions in REMAP-CAP.

Critical Care Reviews' Rob Mac Sweeney talks with Dr. Scott Berry about the statistical plan of REMAP-CAP.

Critical Care Reviews' Rob Mac Sweeney talks with professor Steve Webb about the design of REMAP-CAP. In this episode we describe the rationale behind the trial and its origin.

Welcome to our audio round up of everything on the blog during September. It's been a relatively quiet on the blog post this month, but we chat through not only blogposts on the REMAP-CAP trial, TXA in Head Injury and the ISARIC COVID Risk prediction tool, but also the situation in the North of England and the recent RCEM Virtual Conference. The numbers of Lesson Plans available continue to grow. We've had some great feedback following their use in induction. If tyou've not seen them yet, do have a look and let us know what you think. If you're interesed in learning more about Baysian thinking this Lesson Plan is a good place to start. Take care, Iain  

Critical Care Reviews' Rob Mac Sweeney dives into the details of the first REMAP-CAP results with senior investigators Derek Angus and Tony Gordon. In this episode we discuss the corticosteroids manuscript published in JAMA and put the results into context.